Twist Bioscience price target lowered to $37 from $43 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on Twist Bioscience to $37 from $43 and keeps an Overweight rating on the shares ahead of the company’s fiscal Q1 results. The analyst sees downside risk to short-term estimates, but says investors are likely to "step in on shares" and look through any Q1 weakness if management’s commentary on gross margin drivers are enough to instill confidence in hitting its long-term targets.